HERE ARE A FEW MORE GOOD IDEAS!!
INTERNATIONAL LABORATORIES CAN NOW RENDER DANGEROUS CORONA VIRUS SUCH AS COVID-19...HARMLESS! THE COMMON COLD IS ALSO A CORONA VIRUS AND IT IS A MONEY MAKER FOR PHARMACEUTICAL COMPANIES BECAUSE IT IS NON-LETHAL.
BLOCKING THE SYMPTOMS OF THE COMMON COLD IS GREAT FOR BUSINESS BUT WHEN IT COMES TO CURING THE COMMON COLD, THAT IS NOT SO GREAT FOR THE PRODUCERS OF ASPIRIN AND TYLENOL AND ADVIL...ETC. BIG PHARMA IS FUNNELLING IN BILLIONS BY SIMPLY BLOCKING THE SYMPTOMS AND ALLOWING THE VIRUS TO SURVIVE.
1. BLOCKING THE SYMPTOMS OF THE COMMON COLD VIRUS IS A MULTI MILLION DOLLAR INDUSTRY. THE COLD VIRUS HAS A ROUND CORONA SHAPE AND IS PART OF THE CORONA FAMILY AND FOR DECADES THE COMMON COLD WITH IT'S MORE SERIOUS COUSIN, THE FLU, HAVE HELPED TO CREATE AN EXTREMELY LUCRATIVE BUSINESS FOR THE PHARMACEUTICAL COMPANIES.
2. AS THEY ARE FOR THE MOST PART NON LETHAL, THE COLD AND FLU VIRUS MAY OR MAY NOT BE PROTECTED FROM COMPLETE DESTRUCTION BY THE SAME COMPANIES NOW PRODUCING VACCINES FOR THEIR MORE LETHAL COUSIN, THE COVID-19 VIRUS.
3.. A FEW IMPORTANT LABORATORIES AND THEIR GOVERNMENT SPONSORS ARE THREATENING THE ECONOMIC STABILITY OF MANY "SYMPTOM" BLOCKING COMPANIES BY CREATING AN HONEST AND ABSOLUTE CURE FOR THE COMMON COLD ALONG WITH ALL OF IT'S CORONA COUSINS, INCLUDING COVID 19.
4. TODAY, LABORATORY RESEARCHERS ARE USING CRISPR-CAS 9 TO TRANSFORM DEADLY VIRUS INTO BENIGN LIFE SAVING VIRUS. NEW VACCINES AND GENETIC MODIFICATION METHODS ARE NOW EFFECTIVELY PROVIDING PROTECTION AGAINST COVID-19 AND THE FLU AND THE COLD VIRUS,
PROTECTING AGAINST "CORONA" VIRUSES.
ALONG WITH VACCINES, LABORATORY RESEARCHERS HAVE DISCOVERED WAYS AND METHODS SUCH AS "CRISPER-CAS 9" AND "TIPS" TO ALTER THE GENES OF DANGEROUS VIRUS IN ORDER TO RENDER THE CORONA VIRUS MUTE. OF COURSE THESE DISCOVERIES WILL FINANCIALLY ENDANGER COMPANIES PRODUCING SYMPTOM BLOCKING AND CASH MAKING PRODUCTS LIKE: ASPIRIN, TYLENOL ADVIL...ETC.
CONCLUSION: Scientific breakthroughs are creating a future without deadly diseases.
N.J.R.